Independent
Tenure on this board
2.2 yrs
Also a director at
Syndax Pharmaceuticals Inc (SNDX)Arcus Biosciences Inc (RCUS)Zura Bio Ltd (ZURA)Damora Therapeutics Inc (DMRA)
Meeting calendar
SGMT · Annual meeting · Friday, June 12, 2026
Sagimet Biosciences Inc
4 nominees · 2 ballot items.
Stockholders will vote to elect four Class III directors to three-year terms expiring in 2029 and to ratify the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the 2026 fiscal year.
Market cap
$508M
1Y TSR
+21.2%
Board grade
C+
Record date
Apr 17, 2026
Filing
DEF 14A
Meeting concluded · Jun 12, 2026
Follow how the vote landed and what changed on Sagimet Biosciences Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot2
- 1
Election of Class III Directors for a Three-Year Term Expiring in 2029
ManagementBoard: FORElection of four Class III director nominees (Jennifer Jarrett, Anne Phillips, M.D., David Happel and George Kemble, Ph.D.) each to serve a three‑year term expiring in 2029.
- 2
Ratification of Appointment of KPMG LLP as Independent Registered Public Accounting Firm for 2026
ManagementBoard: FORRatify the Audit Committee’s appointment of KPMG LLP as the Company’s independent registered public accounting firm for the 2026 fiscal year.
Director elections
Nominees on the ballot4
Independent
Tenure on this board
2.2 yrs
Also a director at
Vtv Therapeutics Inc (VTVT)
Not independent
Tenure on this board
9.0 yrs
Not independent
Tenure on this board
11.0 yrs
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | BALYASNY ASSET MANAGEMENT L.P. | 5.8% | 3,626,113 | $28M |
| 2 | Woodline Partners LP | 4.8% | 3,000,652 | $23M |
| 3 | SILVERARC CAPITAL MANAGEMENT, LLC | 4.7% | 2,927,698 | $23M |
| 4 | BlackRock, Inc. | 4.3% | 2,671,054 | $21M |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 4.1% | 2,566,272 | $20M |
| 6 | Caligan Partners LPActivist | 4.0% | 2,500,000 | $19M |
| 7 | BVF INC/IL | 4.0% | 2,500,000 | $19M |
| 8 | Affinity Asset Advisors, LLC | 4.0% | 2,497,864 | $19M |
| 9 | FEDERATED HERMES, INC. | 3.4% | 2,083,333 | $16M |
| 10 | GREAT POINT PARTNERS LLC | 3.3% | 2,029,933 | $16M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Sagimet Biosciences Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Angiodynamics IncANGO
Annual meeting·Nov 17, 2026·$487M
Entera Bio LtdENTX
Special meeting·Nov 24, 2026·$480M
Tilray Brands IncTLRY
Annual meeting·Nov 18, 2026·$474M
Weave Communications IncWEAV
Special meeting·Oct 22, 2026·$591M
Wave Life Sciences IncWVE
Annual meeting·Nov 12, 2026·$629M
Galectin Therapeutics IncGALT
Annual meeting·Dec 3, 2026·$374M
Reference
Frequently asked questions
- When is the Sagimet Biosciences Inc 2026 annual meeting?
- Sagimet Biosciences Inc (SGMT) holds its 2026 annual shareholder meeting on Friday, June 12, 2026.
- What is the record date for the Sagimet Biosciences Inc 2026 meeting?
- The record date for the Sagimet Biosciences Inc 2026 meeting is Friday, April 17, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Sagimet Biosciences Inc's 2026 meeting?
- The board is presenting 4 director nominees at the Sagimet Biosciences Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Sagimet Biosciences Inc 2026 meeting?
- Shareholders will vote on 2 proposals at the Sagimet Biosciences Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.